146 related articles for article (PubMed ID: 2667348)
1. Practical considerations of recombinant human erythropoietin therapy.
Paganini EP; Latham D; Abdulhadi M
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):19-25. PubMed ID: 2667348
[TBL] [Abstract][Full Text] [Related]
2. Management of blood pressure changes during recombinant human erythropoietin therapy.
Levin N
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
[TBL] [Abstract][Full Text] [Related]
3. Monitoring considerations in recombinant human erythropoietin therapy.
Ogden DA
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for recombinant human erythropoietin therapy.
Eschbach JW; Adamson JW
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
[TBL] [Abstract][Full Text] [Related]
6. Who should receive recombinant human erythropoietin?
Van Stone JC
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
[TBL] [Abstract][Full Text] [Related]
7. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
Delano BG
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
[TBL] [Abstract][Full Text] [Related]
8. Resistance to recombinant human erythropoietin therapy: a real clinical entity?
Stivelman JC
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):8-11. PubMed ID: 2669085
[TBL] [Abstract][Full Text] [Related]
9. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
Van Wyck DB
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
Frenken LA; Verberckmoes R; Michielsen P; Koene RA
Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
Nissenson AR
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):25-31. PubMed ID: 2669083
[TBL] [Abstract][Full Text] [Related]
12. Iron management during recombinant human erythropoietin therapy.
Van Wyck DB
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
[TBL] [Abstract][Full Text] [Related]
13. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
Radermacher J; Koch KM
Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
[TBL] [Abstract][Full Text] [Related]
14. Impact of erythropoietin on the dialysis prescription.
Van Wyck DB
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
[TBL] [Abstract][Full Text] [Related]
17. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
Lundin AP
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
[TBL] [Abstract][Full Text] [Related]
18. Review of patients' responses to epoetin alfa therapy.
Krantz SB
Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
[TBL] [Abstract][Full Text] [Related]
19. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
